10.06k followers • 19 symbols Watchlist by Yahoo Finance
Follow this list to discover and track stocks that have been oversold as indicated by the RSI momentum indicator within the last week. A stock is oversold when the RSI is below 30. This list is generated daily, ranked based on market cap and limited to the top 30 stocks that meet the criteria.
Chunghwa Telecom Co., Ltd.
Horizon Therapeutics Public Limited Company
Nuance Communications, Inc.
LHC Group, Inc.
YETI Holdings, Inc.
Equinox Gold Corp.
STAAR Surgical Company
SailPoint Technologies Holdings, Inc.
Nu Skin Enterprises, Inc.
Pacira BioSciences, Inc.
Stock futures were little changed Tuesday evening, struggling for direction after equities sputtered into the close earlier in the day.
There are many pharmaceutical companies are pursuing a vaccine, and the market has already started rewarding some of them. For instance, Novavax (NASDAQ: NVAX) is up a startling 2,500% in 2020. Novavax is not the only winner, however.
Efforts to find treatments for the COVID-19 pandemic have taken top priority at many companies in the space, and today, Novavax (NASDAQ: NVAX) and Regeneron Pharmaceuticals (NASDAQ: REGN) got good news from the federal government. Novavax shares were up more than 30% Tuesday morning as investors reacted positively to the latest news from the biotech. As a major player in the race to find a coronavirus vaccine, Novavax got a shot in the arm from the Department of Health and Human Services.
The funds will support the rapid development and mass production of the biotech's coronavirus vaccine candidate, NVX-CoV2373.
The Zacks Analyst Blog Highlights: Everbridge, Wingstop, BJ's Wholesale Club, Virtu Financial and Ollie's Bargain Outlet
A "black swan" event is a highly unusual, utterly unpredictable happening that throws everybody for a loop. As far as the stock market is concerned, black swans are almost always bad. For instance, 9/11 was a black swan.
Novavax lands a massive $1.6 billion award from the federal government's Operation Warp Speed program.
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that EVO Viva™, STAAR’s innovative presbyopia correcting implantable Collamer® lens ("ICL"), has been approved for sale. STAAR received CE Mark approval of the presbyopic indication for its EVO+ Visian® ICL with Aspheric (EDOF) Optic, commercially marketed as "EVO Viva", from its European Notified Body, DEKRA, on July 2, 2020. EVO Viva will initially be available to patients through select eye doctors in Spain, Germany and Belgium. Broader availability of the lens will follow in Europe and other markets recognizing the CE Mark over the coming months. An introductory video highlighting EVO Viva’s market positioning for countries that accept the CE Mark is included with this press release.
Novavax has signed a deal worth up to $1.6bn with the US government’s Operation Warp Speed vaccine programme, securing more federal funds than any other company behind a potential Covid-19 inoculation. The New York-listed company, which has yet to have any vaccines approved, plans to use the money to embark on a late-stage clinical trial and produce 100m doses of its vaccine candidate by January. Novavax joins big pharmaceutical companies Johnson & Johnson, Pfizer, Merck and AstraZeneca in Operation Warp Speed, a US health department project touted by President Donald Trump, which aims to accelerate the development of a Covid-19 vaccine candidate.
The U.S. government has awarded Novavax Inc $1.6 billion to cover testing and manufacturing of a potential vaccine for the novel coronavirus in the United States, with the aim of delivering 100 million doses by January. The award announced by the U.S. Department of Health and Human Services is the biggest yet from "Operation Warp Speed," the White House initiative aimed at accelerating access to vaccines and treatments to fight COVID-19, the respiratory disease caused by the coronavirus. Shares in Gaithersburg, Maryland-based Novavax rose 29% to $102 in morning trading.
Restaurant Brands (QSR) is likely to benefit from various sales-building initiatives. However, coronavirus pandemic continues to hurt comps.
Nu Skin Enterprises, Inc. (NUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Manufacturing activity is increasing in the country despite the number of new COVID-19 cases, pointing at a recovering U.S. economy.
Apart from the large-cap specific three major stock indexes, the mid-cap specific S&P 400 also advanced 23.3% in the last quarter.
The stock market fell Tuesday, but is a sustained pullback in the offing. Tesla and EV rival Nio keeps moving early. Facebook is in focus after execs met with ad boycott organizers.
China's Clover Biopharmaceuticals Inc has received $66 million in investment from the Coalition for Epidemic Preparedness Innovation (CEPI) to bolster the testing of a potential COVID-19 vaccine, the global epidemic response group said on Wednesday. Last month, Clover became the sixth Chinese developer of a potential COVID-19 vaccine to move into human trials by launching a study in Australia to test its vaccine with boosters. The foundation said the funding aims to help produce hundreds of millions of doses of the potential vaccine per year and if the early stage trials are successful, it expects to provide "significant" additional support.
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
Pacira BioSciences, Inc. (PCRX) today announced the pricing of $350.0 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $300.0 million aggregate principal amount of notes. Pacira also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $52.5 million aggregate principal amount of notes.
Stocks to consider as biotech company Novavax gets $1.6 billion in federal aid for Covie-19 vaccine Continue reading...
After notching a roughly 18% gain in April and May, the S&P 500 has gained only about 2% since early June. Here are Barron’s picks for S&P 500 stocks with attractive, but not ultrahigh, dividend yields.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]